Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase ...

The US’ Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi, the brand name for its 40mg minocycline hydrochloride extended-release capsules, to be used in the treatment ...

TUESDAY, Nov. 12, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Emrosi (minocycline hydrochloride) for the treatment of inflammatory rosacea in adults. The extended ...

The FDA has approved Emrosi for the treatment of rosacea in adults, Journey Medical Corporation announced in a press release. “For many of the millions of patients diagnosed with rosacea ...

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder. The new capsule formulation of the ...

The FDA has approved an antibiotic called minocycline for the treatment of rosacea in adults. The drug, which is taken orally, will be sold under the brand name Emrosi.

FDA approves Journey Medical’s Emrosi to treat inflammatory lesions of rosacea The long-term skin condition affects more than 16 million people in the US The US Food and Drug Administration (FDA) has ...

Emrosi is a FDA-approved treatment for inflammatory lesions of rosacea, containing 40 mg of Minocycline Hydrochloride in modified-release capsules. When did the national TV segment on Emrosi air?

The FDA approved minocycline hydrochloride extended-release capsules (Emrosi) for treating inflammatory lesions of rosacea in adults, drugmaker Journey Medical announced on Monday.

“These compelling Phase 3 results reinforce the potential of Emrosi to become a new standard of care for patients with rosacea. Emrosi is the lowest oral dose of minocycline approved by the FDA ...

Journey Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea.

The analysis determined that differences in body weight did not affect the efficacy of Emrosi in the two Phase 3 trials, which supported its November 2024 FDA approval.